Formulation and Optimization of Polymeric Nanoparticles for Intranasal Delivery of Lorazepam Using Box-Behnken Design: In Vitro and In Vivo Evaluation

Table 2

Effect of independent process variables on dependent variable.

Formulation	PLGA mg/mL	Poloxamer mg/mL	w/o phase volume ratio	Drug conc. Mg/mL	𝑧-Average d·nm; (±SD)	% Drug entrapment; (±SD)	PDI; (±SD)
1.	35	2	6	1	211 ± 0.11	70 ± 1.3	0.183 ± 0.002
2.	35	2	6	5	220 ± 0.8	88.48 ± 0.8	0.150 ± 0.003
3.	10	8.50	10	3	176 ± 0.5	83 ± 0.5	0.048 ± 0.001
4.	35	8.50	2	1	177 ± 1.2	71 ± 1.5	0.17 ± 0.004
5.	10	2	6	3	205 ± 0.9	81 ± 0.7	0.315 ± 0.003
6.	10	8.50	6	5	177 ± 1.6	83.5 ± 0.5	0.110 ± 0.002
7.	10	8.50	2	3	184 ± 1.5	75 ± 0.35	0.078 ± 0.002
8.	35	8.50	6	3	197 ± 0.5	86.6 ± 0.65	0.112 ± 0.004
9.	60	8.50	6	1	271 ± 0.8	76 ± 0.22	0.24 ± 0.001
10.	35	15	6	5	192 ± 1.4	84.3 ± 0.35	0.19 ± 0.001
11.	10	15	6	3	177 ± 0.6	80 ± 2.1	0.04 ± 0.003
12.	60	2	6	3	318 ± 1.2	90.1 ± 0.8	0.441 ± 0.002
13.	35	15	10	3	191 ± 1.5	83.5 ± 1	0.17 ± 0.003
14.	60	15	6	3	228 ± 0.5	82 ± 0.4	0.15 ± 0.001
15.	60	8.50	2	3	241 ± 0.4	88 ± 0.85	0.309 ± 0.005
16.	35	15	6	1	182.5 ± 0.5	66.4 ± 0.2	0.09 ± 0.002
17.	35	2	2	3	215 ± 0.7	87.83 ± 0.1	0.15 ± 0.005
18.	60	8.50	6	5	261 ± 0.5	89 ± 1.7	0.20 ± 0.001
19.	35	8.50	2	5	193 ± 1.1	88 ± 1.5	0.10 ± 0.002
20.	10	8.50	6	1	167 ± 0.8	65.5 ± 1.1	0.21 ± 0.005
21.	35	8.50	10	1	192 ± 1.7	69 ± 0.6	0.28 ± 0.001
22.	35	2	10	3	241 ± 1.5	88 ± 1.5	0.21 ± 0.003
23.	35	8.50	10	5	202 ± 1.2	87 ± 1	0.19 ± 0.002
24.	35	15	2	3	186 ± 1.5	84 ± 0.8	0.15 ± 0.002
25.	60	8.50	10	3	283 ± 0.7	88 ± 1.4	0.15 ± 0.006
26.	35	8.50	6	3	193 ± 0.5	85.12 ± 0.7	0.102 ± 0.004